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Abstract: Objective: Since obesity has been associated with a higher inflammatory burden and worse
response to therapy in patients with chronic inflammatory rheumatic diseases (CIRD), we aimed to
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confirm the potential association between body mass index (BMI) and disease activity in a large series
of patients with CIRDs included in the Spanish CARdiovascular in rheuMAtology (CARMA) registry.
Methods: Baseline data analysis of patients included from the CARMA project, a 10-year prospective
study of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis
(PsA) attending outpatient rheumatology clinics from 67 Spanish hospitals. Obesity was defined
when BMI (kg/m2) was >30 according to the WHO criteria. Scores used to evaluate disease activity
were Disease Activity Score of 28 joints (DAS28) in RA, Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) in AS, and modified DAS for PsA. Results: Data from 2234 patients (775 RA, 738 AS,
and 721 PsA) were assessed. The mean ± SD BMI at the baseline visit were: 26.9 ± 4.8 in RA,
27.4 ± 4.4 in AS, and 28.2 ± 4.7 in PsA. A positive association between BMI and disease activity in
patients with RA (β = 0.029; 95%CI (0.01–0.05); p = 0.007) and PsA (β = 0.036; 95%CI (0.015–0.058);
p = 0.001) but not in those with AS (β = 0.001; 95%CI (−0.03–0.03); p = 0.926) was found. Disease
activity was associated with female sex and rheumatoid factor in RA and with Psoriasis Area Severity
Index and enthesitis in PsA. Conclusions: BMI is associated with disease activity in RA and PsA, but
not in AS. Given that obesity is a potentially modifiable factor, adequate control of body weight can
improve the outcome of patients with CIRD and, therefore, weight control should be included in the
management strategy of these patients.
Keywords: body mass index; obesity; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis
and disease activity
1. Introduction
Obesity constitutes a major epidemic, in particular in developed countries. It af-
fects around 35% of the general population according to the World Health Organization
(WHO) [1]. In Spain, it reaches 21.6% of the global population, according to data from
the Nutritional Study of the Spanish Population (ENPE-2015) [2]. Some studies suggest
that there is a higher prevalence of obesity in individuals with rheumatoid arthritis (RA),
psoriatic arthritis (PsA) [3–5], and ankylosing spondylitis (AS) [6].
A number of studies have confirmed that adipose tissue is a metabolically active
organ, representing an important source of inflammatory mediators, known as adipokines
or adipocytokines. They promote a pro-inflammatory state in obese subjects, establishing
obesity as a low-grade inflammatory disease [7,8].
Higher body mass index (BMI) values are negatively associated with anti-TNF drug
levels in plasma and, as a consequence, obesity has been associated with higher disease
activity rates and worse response to therapies [9–12]. The relationship between obesity and
disease activity has been reflected in some studies in patients with RA and PsA. Regarding
AS, this relationship is less clear. However, some studies suggest a possible link between
disease activity in patients with AS and excess fatty tissue [13,14]. In this regard, higher
BMI values have been associated with lower response rates mainly to infliximab (IFX) [15]
and other anti-TNF agents in patients with spondyloarthritis [16,17].
Taking all these considerations into account, the purpose of the present study was
to confirm the potential association between BMI and disease activity in a large series of
patients with chronic inflammatory rheumatic diseases (CIRD) included in the Spanish
CARdiovascular in rheuMAtology (CARMA) registry.
2. Patients and Methods
2.1. Study Design
The CARdiovascular in rheuMAtology (CARMA) project is a prospective 10-year
follow-up cohort study designed to determine the risk of cardiovascular mortality in
patients with CIRDs compared to a cohort of patients without CIRD [18]. For the present
study, a cross-sectional analysis of the initial visit has been performed to determine the
relationship between disease activity and BMI at the baseline visit (time of recruitment).
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2.2. Patient Recruitment
All Spanish public hospitals (university and general hospitals) with Rheumatology
Units included in the Spanish Rheumatology Society (Sociedad Española de Reumatología-
SER) database, which includes more than 90% of the country’s hospitals, were invited
to participate in the registry. Finally, 67 institutions (63.2% of all centers contacted) were
included in the project. Overall, the patients recruited for the study were 2234. They
attended rheumatology outpatient clinics at tertiary or secondary care centers between
July 2010 and January 2012. Patients were included in the registry if they were older than
18 years and met at least 4 criteria of the American College of Rheumatology (ACR) 1987
for RA [19], the modified New York criteria for definite AS [20] or, in the case of PsA, the
Moll and Wright criteria [21].
Information regarding the sample size and the baseline characteristics of the recruited
participants, patients, and controls has previously been described by Castañeda et al. [18].
The study protocol was performed according to the principles of the Helsinki Declaration
and it was approved by the Ethics Committee for Clinical Research of Lugo, Galicia (Spain),
and subsequently also in each participant center (protocol number: 2009/077).
2.3. Variables and Operative Definitions
All included patients were evaluated on a continuous and systematic basis. To verify
the quality of the information, an on-site evaluation of the follow-up data was performed
randomly in 15% of the selected patients. The primary variable studied was the disease
activity, which was measured through the Disease Activity Score of 28 joints (DAS28) [22] in
the baseline visit for patients with RA. In the case of PsA, it was assessed through modified
DAS28 [23], and by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in AS
patients [24]. The explanatory variable was the BMI measured in kg/m2.
Potential confounding factors included socio-demographic factors (such as age, sex,
and education level), disease-specific variables (rheumatoid factor (RF), anti-citrullinated
peptide antibodies (ACPA), positivity for HLA-B27, erythrocyte sedimentation rate (ESR,
mm/h) by Westergren method, C-reactive protein (CRP, mg/L)), DAS28-ESR, modified
DAS for PsA, Health Assessment Questionnaire (HAQ, from 0 to 3), Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI, from 0 to 10) and Bath AS Functional Index
(BASFI, from 0 to 10), duration of disease, and administered therapies. The variables of
physical activity and smoking are collected through an interview with the patient. Physical
activity was classified into three categories: mild, moderate, and high physical activity
depending on the hours of exercise per week. Height was measured in the patients at the
beginning of the study (visit 0). Data on medication are collected by reviewing the medical
history (see supplementary material of [18]).
2.4. Statistical Analysis
A baseline descriptive analysis was performed. Numerical variables with a normal dis-
tribution were expressed as mean and standard deviation (SD). Non-normally distributed
variables were shown as the median and interquartile range (IQR, P25–P75). The absolute
and relative frequencies of the qualitative variables were also calculated.
Analyses of the main demographic and clinical variables stratified by the type of
disease were done. Furthermore, a stratified analysis was performed through linear
regression for each group according to activity indices and BMI (kg/m2). Moreover, socio-
demographic characteristics and clinical features were analyzed.
To study the relationship between disease activity and BMI (kg/m2), three explanatory
models of linear regression were constructed, one for each disease, calculating the beta (β)
coefficient, with 95% confident interval (CI) and adjusting for potential confounding factors.
Data management and statistical analysis were centralized at the Research Unit of the
Spanish Rheumatology Society. All analyses were performed using Stata 13.1 copyright
1985–2013 StataCorp LP (Lakeway Drive College Station, Texas, USA).
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3. Results
3.1. General Characteristics of the Patients
The total number of patients included in the study was 2234 (775 RA, 738 AS, 721 PsA).
Socio-demographic and clinical characteristics of the patients included have been described
in previous studies [18] (Table 1), with an increased prevalence of women in the RA group
(74.9%) and a greater percentage of men in AS group (72.9%), while sex distribution was
almost similar in PsA patients. The average age in patients with RA was higher (57.1 years)
than in the other two groups. By contrast, the average BMI and the frequency of obesity
were higher in patients with PsA. Furthermore, diabetes was more frequent in PsA patients.
The percentage of active smokers was higher in the AS group (34.4%). Remarkably, the
majority of CIRD patients included in the study had low disease activity at the time
of inclusion in the registry because patients were followed up in outpatient clinics of
Rheumatology, mostly under tight control conditions of management of the disease. In
keeping with that, the percentage of patients receiving biologic therapy ranged between
41.4% in RA up to 47.2% in AS (Table 1).









(n = 721) p
Age at inclusion, years, mean (SD) 57.1 (12.3) 48.1 (11.7) 51.8 (12.0) <0.001
Age at the beginning of disease,
years, mean (SD) 45.8 (13.4) 29.7 (11.8) 39.5 (13.3) <0.001
Female sex, n (%) 581 (75.0) 200 (27.1) 327 (45.4) <0.001
BMI, kg/m2, mean (SD) 26.9 (4.8) 27.4 (4.4) 28.2 (4.7) 0.005
Physical activity 462 (66.1) 453 (69.7) 409 (62.9) 0.035
Smoking
Current 172 (24.4) 224 (34.1) 136 (20.6)
<0.001Past 188 (26.7) 212 (32.3) 216 (32.7)
Never 345 (48.9) 221 (33.6) 308 (46.7)
Ethnicity
Caucasic 679 (96.6) 643 (97.9) 654 (99.2)
<0.001Hispanic 20 (2.8) 6 (0.9) 2 (0.3)
Other 4 (0.1) 8 (1.2) 3 (0.5)
Educational level
Basic 59 (8.5) 25 (3.8) 32 (4.9)
<0.001
Primary 367 (52.6) 257 (39.4) 269 (41.2)
Secondary 171 (24.5) 199 (30.5) 189 (28.9)
University 101 (14.5) 172 (26.3) 163 (25.0)
Obesity (BMI ≥ 30), n (%) 180 (23.2) 186 (25.2) 209 (29.1) <0.001
Disease duration, years 8.0 (3.0–14.0) 15.0 (8.0–26.0) 9.0 (4.0–16.0) <0.001
DAS28-ESR, mean (SD) 3.2 (1.2) - 3.0 (1.3) 0.005
BASDAI (0–10), median (P25–P75) - 3.5 (1.7–5.3) - -
HAQ (1–3), median (P25–P75) 0.5 (0.1–1.1) - 0.4 (0.0–0.9) <0.001
BASFI (0–10), median (P25–P75) - 3.1 (1.3–5.2) - -
ESR, mm/1st h, median (P25–P75) 17.0 (9.0–29.0) 10.0 (6.0–21.0) 12.0 (6.0–21.0) <0.001
CRP, mg/L, median (P25–P75) 3.1 (1.2–8.0) 3.6 (1.6–8.9) 2.9 (1.4–6.1) 0.001
ACPA positive (%) 420 (59.6) -
RF positive (%) 541 (76.7) -
HLA-B27 positive (%) 498 (75.8)
Onicopathy, n (%) 254 (38.5) -
PASI, median (P25–P75) 0.6 (0.0–2.1) -
Enthesitis, median (P25–P75) 0.0 (0.0–1.0) -










(n = 721) p
Conventional DMARDs, n (%) 619 (87.8) 209 (31.8) 491 (74.4) <0.001
Biologic DMARDs, n (%) 292 (41.4) 310 (47.2) 278 (42.1) 0.068
GC (ever treated), n (%) 320 (45.4) 54 (8.2) 117 (17.7) <0.001
BMI: body mass index; DAS28-ESR: Disease Activity Score using 28 joints-erythrocyte sedimentation rate; BASDAI: Bath Ankylosing
Spondylitis (AS) Disease Activity Score; HAQ: Health Assessment Questionnaire; BASFI: Bath AS Functional Index; CRP: C-reactive
protein; ACPA: anti-cyclic citrullinated peptide antibodies; RF: rheumatoid factor; HLA-B27: histocompatibility antigen; PASI: Psoriasis
Area Severity Index; DMARD(s): Disease-modifying antirheumatic drugs; GC: glucocorticoids. Data expressed as median (P25–P75) unless
specified. Dichotomous variables are expressed as n and percentages (%); SD: standard deviation.
3.2. Association between Body Mass Index and Disease Activity
The effect of BMI on disease activity, estimated as β-coefficient by multivariate linear
regression, is shown in Table 2. We found a positive association between BMI and disease
activity in patients with RA (β-coefficient: 0.029; 95% CI: 0.01–0.05; p = 0.007) and in those
with PsA (β-coefficient: 0.036; 95% CI: 0.015–0.058; p = 0.001). By contrast, there was no
significant association between BMI and disease activity in patients with AS (β-coefficient:
0.001; 95% CI: −0.026–0.03; p = 0.926). When categorizing BMI variable as normal weight
(BMI < 25), overweight (BMI: 25–30), and obesity (BMI > 30), similar significance was
maintained in patients with RA (B-coeff: 0.32; 95% CI:0.067–0.571; p = 0.013), while in
PsA, the significance remained only at limited values (B-coeff: 0.27; 95% CI:−0.0026–
0.537; p = 0.05), probably due to the reduction in the number of patients in each group,
maintaining non-significant values in patients with AS (B-coeff: 0.073; p = 0.662).
In patients with RA, female sex (β-coefficient: 0.546; 95% CI: 0.316–0.775; p < 0.001)
and rheumatoid factor status (seropositivity for RF) (β-coefficient: 0.328; 95% CI: 0.106–
0.549; p = 0.004) also showed a positive association with disease activity, while physical
activity revealed a negative association with disease activity (β-coefficient: −0.280; 95% CI:
−0.479–(−0.081); p = 0.006) (Table 2).
Besides BMI, female sex (β-coefficient: 0.720; 95% CI: 0.524–0.916; p < 0.001), Psoriasis
Area Severity Index (PASI) (β-coefficient: 0.038; 95% CI: 0.012–0.066; p = 0.005), and enthe-
sitis (β-coefficient: 0.256; 95% CI: 0.199–0.313; p < 0.001) were also positively associated
with disease activity in PsA (Table 2).
As observed in RA and PsA, female sex was also associated with disease activity in
patients with AS (β-coefficient: 0.565; 95% CI: 0.299–0.832; p < 0.001) (Table 2).
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β 95% CI p-Value β 95% CI p-Value β 95% CI p-Value
BMI (kg/m2) 0.029 (0.01, 0.05) 0.007 0.001 (−0.03, 0.03) 0.926 0.036 (0.015, 0.058) 0.001
Age at inclusion −0.003 (−0.01, 0.004) 0.312 −0.005 (−0.02, 0.005) 0.348 −0.003 (−0.011, 0.004) 0.325
Sex (reference, male) 0.545 (0.316, 0.775) <0.001 0.565 (0.299, 0.832) <0.001 0.720 (0.524, 0.916) <0.001
Ethnicity (reference, Caucasic)
Hispanic −0.234 (−0.810, 0.343) 0.426 0.422 (−0.788, 1.633) 0.493 1.077 (−0.529, 2.684) 0.188
Other −0.789 (−1.986, 0.406) 0.195 0.119 (−1.095, 1.334) 0.847 −1.370 (−2.977, 0.237) 0.095
Physical activity (reference, no) −0.280 (−0.479, −0.081) 0.006 0.0009 (−0.260, 0.262) 0.994 −0.100 (−0.296, 0.095) 0.313
Educational level
(ref., Primary)
Primary −0.136 (−0.481, 0.201) 0.437 0.374 (−0.254, 1.004) 0.242 −0.358 (−0.80, 0.083) 0.112
Secondary −0.350 (−0.732, 0.035) 0.075 0.332 (−0.311, 0.975) 0.311 −0.538 (−0.999, −0.767) 0.022
University −0.137 (−0.551, 0.275) 0.513 0.321 (−0.341, 0.984) 0.341 −0.540 (−1.009, −0.075) 0.024
Smoking (ref., current smokers)
Past smokers (>1 year) 0.102 (−0.166, 0.370) 0.455 −0.043 (−0.330, 0.242) 0.765 0.081 (−0.188, 0.352) 0.552
Never smokers 0.081 (−0.157, 0.319) 0.504 0.010 (−0.279, 0.300) 0.942 −0.049 (−0.299, 0.200) 0.696
Rheumatoid factor +
(reference, no) 0.328 (0.106, 0.549) 0.004 NA NA
HLA-B27 + (reference, no) NA −0.099 (−0.376, 0.178) 0.484 NA
BASFI NA 0.656 (0.608, 0.706) <0.001 NA
PASI NA NA 0.038 (0.012, 0.066) 0.005
Enthesitis NA NA 0.256 (0.199, 0.313) <0.001
Onicopathy (reference, no) NA NA 0.155 (−0.034, 0.346) 0.109
Conventional DMARDs
(ref., no) −0.059 (−0.341, 0.223) 0.680 0.028 (−0.023, 0.286) 0.829 0.193 (−0.029, 0.415) 0.089
Biologic DMARDs (reference,
no) 0.095 (−0.10, 0.29) 0.338 −0.431
(−0.665,
−0.198) <0.001 −0.353 (−0.553, −0.154) 0.001
Glucocorticoids (reference, no) 0.187 (0.001, 0.373) 0.049 0.373 (−0.054, 0.802) 0.087 0.326 (0.083, 0.570) 0.008
BASFI: Bath Ankylosing Spondylitis (AS) Functional Index; BMI: body mass index; CARMA: CARdiovascular in RheuMAtology; CIRD: chronic inflammatory rheumatic diseases; DMARD(s): disease-modifying
anti-rheumatic drugs; HLA-B27: Human leucocyte antigen B27; PASI: Psoriasis Area Severity Index. Data are expressed as β-coefficients (95% CI) and p-values. NA: not applicable.
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4. Discussion
The main findings of this study support an association of BMI with disease activity in
RA and PsA but not with AS. In addition, specific features of each CIRD were associated
with disease activity. It was the case for RF status in patients with RA and PASI and the
presence of enthesitis in those with PsA. Central obesity is one of the components of the
metabolic syndrome that is frequently observed in patients with CIRD, in particular in
those with RA and PsA [25–27].
The reason for the absence of the association of BMI with disease activity in patients
with AS from the CARMA project is unknown. With respect to this, AS patients included
in the CARMA cohort had low disease activity and almost half of them were undergoing
biologic therapy. In this regard, it may be of potential interest to highlight that the anti-TNF
monoclonal antibody-IFX was more frequently used in AS (18.3%) than in RA (6.2%) and
PsA (10.1%). Given that IFX is a biological agent that is administered adjusted to the
weight of the subject, we wondered if this could lead to an optimal response and less
disease activity in this group of patients. According to this possibility, Micheroli et al.
reported that axial spondyloarthritis obese patients treated with IFX had a better response
compared to those treated with other anti-TNF agents not adjusted to corporal weight [16].
Another possible explanation may be that the implication of the metabolic syndrome and,
consequently, of the proinflammatory adipokines in AS appears to be less important than
that played in the other two CIRDs. On the other hand, our data also supported the
potential beneficial effect of regular physical activity and weight loss on the control of the
underlying disease in individuals with RA.
Obesity and overweight have an important role in the development of psoriasis and
PsA. In a cohort study among 75,395 individuals with psoriasis (43% male, mean age
of 52 years, and mean follow-up of 5 years) conducted in the UK, 976 developed PsA
(incidence rate of 26.5 per 10,000 person-years) [28]. The PsA incidence rates augmented
with increasing BMI. Compared to psoriasis patients with BMI < 25 kg/m2, the relative
risk for developing PsA was 1.09 (0.93–1.28) for BMI from 25.0 to 29.9, 1.22 (1.02–1.47) for
BMI from 30.0 to 34.9, and 1.48 (1.20–1.81) for BMI ≥ 35 [28]. In another study including
89,049 participants from the Nurses’ Health Study II followed over a 14-year period, 146
incident PsA cases were identified during 1,231,693 person-years of follow-up. Among all
participants, BMI was associated with an increased risk of incident PsA [29]. There was a
graded positive association between weight change from age 18 years, measures of central
obesity, and risk of PsA. The analysis among participants developing psoriasis during the
follow-up revealed a similar association, indicating an increased risk of PsA associated
with obesity among patients with psoriasis [29]. These two studies suggest that obesity is
associated with an increased risk of incident PsA and supports the importance of weight
control among psoriatic patients who often suffer from metabolic syndrome and obesity.
As previously reported by other authors [17,30–33], obese patients from the CARMA cohort
were treated more commonly with biologic therapies than normal-weight individuals.
Finally, besides its direct effect on inflammation through increased proinflammatory
cytokines secretion, obesity can also influence treatment response by modifying pharma-
cokinetics of biologic antirheumatic drugs. In fact, population studies have identified
high body weight as a risk factor for increased clearance of anti-TNF agents, resulting in
shorter half-life and lower serum drug concentrations [34]. By contrast, there is strong
clinical evidence that while TNF blockers may be less effective in obese patients, the efficacy
of T cell co-stimulation inhibition, B-cells depletion, and IL-6 blocking seems not to be
negatively influenced by the amount of body fat [35].
Our study has some strengths. It includes an important national multicenter cohort
of patients with RA, AS, and PsA prospectively followed up at the outpatient clinics to
detect the incidence of cardiovascular events over 10 years of follow-up, being the first
study in our country that tries to establish an association between BMI and inflammatory
activity in patients with these three diseases. However, it has also some limitations. Many
of the patients included in this study had low disease activity at the time of recruitment.
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In fact, our patients were under a tight control strategy and a high number of them were
undergoing biologic therapy at recruitment. This management may have had decreased
some of the disease activity parameters used, thus interfering in the results. In this regard,
obesity is a modifiable factor in our clinical practice that not only plays an important role
in cardiovascular risk and morbidity but its control would also imply better management
of the inflammatory disease and better efficiency of the treatments, especially biological
agents, used in these patients.
In summary, a relationship between BMI and disease activity was observed in patients
with CIRD from the CARMA cohort, especially in patients with RA and PsA. This finding
could not be demonstrated in patients with AS, where the proportion of patients treated
with biologic therapy was higher, which could have modified the results obtained.
Adequate control over body weight may improve the outcome of patients with in-
flammatory joint diseases and, therefore, weight control should be included in the strategy
of management of these patients.
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